By AstraZeneca said on Friday its experimental precision drug had slowed the progression of a common type of breast cancer in a late-stage trial, a boost for the company after its shares fell in July on results from a separate trial of the same drug for lung cancer. The drug, datopotamab…
Positive Trial Results For AstraZeneca’s Precision Drug Dato-DXd In Breast Cancer – BusinessToday
Comments